Pharmeco, a vertically integrated pharmaceutical group in the healthcare industry, and the Union of Chinese Entrepreneurs in Russia have signed a partnership agreement to develop cooperation between Russian and Chinese organizations and Asia-Pacific countries in pharmacology and the construction of medical facilities. The document was signed by Pharmeco Chairman of the Board of Directors Vladimir Babiy and Union of Chinese Entrepreneurs in Russia President Zhou Liqun.
The agreement was signed on 2 September on the sidelines of the Eastern Economic Forum 2021 at the ‘Invest in Russia with the Russian-Chinese Business Council — Where Trust Is Built’ site, which the Roscongress Foundation and Fund RC-Investments created jointly with the Russian-Chinese Business Council.
Russian-Chinese cooperation in pharmacology is a top priority right now. The experience gained from the pandemic has shown how important it is to work together on health issues. Today, Russia and China are ready to actively cooperate in biotechnology. And the synergistic effect that can be seen in this cooperation suggests that the transborder nature of cooperation and the integration of the two countries’ capabilities are what will provide great opportunities to seriously improve the situation as it pertains to the health of their citizens. For this reason, one of the most important issues in cooperation will be the ability to accelerate the delivery of production equipment for the implementation of biotechnological projects.
The agreement between Pharmeco and the Union of Chinese Entrepreneurs in Russia aims to expand the horizons of cooperation between the two states and lift barriers that are hindering the effective development of business, trade, and economic ties. As part of this agreement, professional mutual consultations will be carried out to establish equal and mutually beneficial relations between the parties to the agreement.
The Chinese medical and pharmaceutical market is currently one of the largest in the world, so Russian companies should pay special attention to their work in introducing innovations into the production process with their key Chinese partners. The expansion of business ties between Russian and Chinese specialists contributes to successful clinical trials and the creation of new drugs in China and Russia, which lays the foundation for building a partnership system in the medical business.
«Our partnership with the Union of Chinese Entrepreneurs in Russia will help expand business ties between Russia and China. The Chinese pharmaceutical market is currently one of the largest and most innovative, so special attention should be paid to working together in innovations in the manufacturing process. We are open to a professional dialogue between leading companies in the healthcare and pharmaceutical industries in Russia and the People’s Republic of China. As part the cooperation agreement that was signed, it is crucial to note the emergence of new opportunities for joint activities — intensifying research and educational cooperation in the medicine industry between the two countries,» Pharmeco Chairman of the Board of Directors Vladimir Babiy said.
«The Business Council supports the exchange of experience and mutually beneficial cooperation in pharmacology. Today, China is one of the leaders in terms of tech development, and Russia has many projects that are appealing to investors. Russia is ready to actively cooperate with the PRC. We need to not only deal with exports and imports, but also transfer technologies between the two countries. Russian pharmaceutical manufacturers are open to partnerships, and the Russian-Chinese Business Council is ready to strengthen and accelerate the development of mutually beneficial bilateral relations between Chinese and Russian companies,» Russian-Chinese Business Council Executive Director Yevgeny Markin said.
Background:
Pharmeco is a vertically integrated pharmaceutical group in the healthcare industry. Pharmeco operates in all major segments of the pharmaceutical industry:
· Organizing the production of a full cycle of modern medicines based on domestic pharmaceutical enterprises that meet modern requirements for production and quality control (GMP)
· Supporting and conducting scientific research and development of domestic innovative drugs
· Implementing joint projects with major foreign pharmaceutical companies
· Ensuring the availability of modern and effective medicines, medical products, and medical equipment throughout Russia via a modern logistics and distribution system
